Tumor biomarkers that identify molecular subtypes and best responders to chemotherapy in patients with PDAC
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Heidelberg, Universität Heidelberg, Dissertation, 2023
- Schlagwort
-
Bauchspeicheldrüsenkrebs
Krebs
Therapie
Bauchspeicheldrüsenkrankheit
- Ereignis
-
Veröffentlichung
- (wo)
-
Heidelberg
- (wer)
-
Universitätsbibliothek Heidelberg
- (wann)
-
2023
- Urheber
- Beteiligte Personen und Organisationen
- DOI
-
10.11588/heidok.00032941
- URN
-
urn:nbn:de:bsz:16-heidok-329416
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
16.08.2023, 04:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zhou, Xu
- Fortunato, Franco
- Universitätsbibliothek Heidelberg
Entstanden
- 2023
Ähnliche Objekte (12)
PDAC-Automobilclub
Circulating Biomarkers to Identify Responders in Cardiac Cell therapy
Author Correction: Circulating Biomarkers to Identify Responders in Cardiac Cell therapy
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
Patient-specific heart simulation can identify non-responders to cardiac resynchronization therapy
Integrating heterogeneous genomic data to accurately identify disease subtypes
Therapeutic strategies targeting Kv10.1 in PDAC
PDAC: Profitieren Hochrisikoindividuen von einer Langzeitüberwachung?
PDAC: Profitieren Hochrisikoindividuen von einer Langzeitüberwachung?
Treatment Switch in Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy
Usefulness of NT-pro BNP monitoring to identify echocardiographic responders following cardiac resynchronization therapy
Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders
PDAC-Automobilclub
Circulating Biomarkers to Identify Responders in Cardiac Cell therapy
Author Correction: Circulating Biomarkers to Identify Responders in Cardiac Cell therapy
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
Patient-specific heart simulation can identify non-responders to cardiac resynchronization therapy
Integrating heterogeneous genomic data to accurately identify disease subtypes
Therapeutic strategies targeting Kv10.1 in PDAC
PDAC: Profitieren Hochrisikoindividuen von einer Langzeitüberwachung?
PDAC: Profitieren Hochrisikoindividuen von einer Langzeitüberwachung?
Treatment Switch in Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy
Usefulness of NT-pro BNP monitoring to identify echocardiographic responders following cardiac resynchronization therapy
Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders
PDAC-Automobilclub
Circulating Biomarkers to Identify Responders in Cardiac Cell therapy
Author Correction: Circulating Biomarkers to Identify Responders in Cardiac Cell therapy
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
Patient-specific heart simulation can identify non-responders to cardiac resynchronization therapy
Integrating heterogeneous genomic data to accurately identify disease subtypes
Therapeutic strategies targeting Kv10.1 in PDAC
PDAC: Profitieren Hochrisikoindividuen von einer Langzeitüberwachung?
PDAC: Profitieren Hochrisikoindividuen von einer Langzeitüberwachung?
Treatment Switch in Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy
Usefulness of NT-pro BNP monitoring to identify echocardiographic responders following cardiac resynchronization therapy